Free Trial
NYSE:ANVS

Annovis Bio Q4 2024 Earnings Report

Annovis Bio logo
$2.33 -0.02 (-0.85%)
Closing price 08/28/2025 03:57 PM Eastern
Extended Trading
$2.33 +0.00 (+0.04%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.38
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$0.43

Annovis Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annovis Bio Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Friday, March 21, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Annovis Bio's Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Annovis Bio Earnings Headlines

Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
See More Annovis Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email.

About Annovis Bio

Annovis Bio (NYSE:ANVS), a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

View Annovis Bio Profile

More Earnings Resources from MarketBeat